Literature DB >> 1984603

Surfactant treatment of full-term newborns with respiratory failure.

R L Auten1, R H Notter, J W Kendig, J M Davis, D L Shapiro.   

Abstract

Surfactant inactivation has been shown to be a significant factor in animal models of lung injury and may also be important in some forms of respiratory failure in full-term newborns. Fourteen full-term newborns with respiratory failure associated with pneumonia (7 patients) and meconium aspiration syndrome (7 patients) were treated with 90 mg/kg of a calf lung surfactant extract, given intratracheally up to every 6 hours for a maximum of four doses. The group mean fraction of inspired oxygen (FI02) before treatment was 0.99 +/- 0.01 SEM, and the mean airway pressure (MAP) was 14.6 +/- 1.0 cm H2O. Patients showed significant improvement in oxygenation after initial surfactant treatment, with the arterial-alveolar oxygenation ratio (a/A ratio) rising from 0.09 +/- 0.01 before surfactant treatment to 0.22 +/- 0.05 by 15 minutes (P = .03) and remaining improved for 6 hours. The oxygenation index, incorporating MAP as well as oxygen variables, also improved significantly from 26.2 +/- 3.1 to 11.2 +/- 1.7 at 15 minutes (P less than .001), with improvement sustained for more than 6 hours. Chest radiographs were blindly scored from 0 (normal) to 5 (severe opacification), and these improved with marginal significance after initial surfactant treatment (from 2.9 +/- 0.2 to 2.5 +/- 0.2, P = .05).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1984603

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  33 in total

Review 1.  Exogenous surfactant: intubated present, nebulized future?

Authors:  Shetal Shah
Journal:  World J Pediatr       Date:  2010-06-12       Impact factor: 2.764

Review 2.  Surfactant therapy for meconium aspiration syndrome: current status.

Authors:  Peter A Dargaville; John F Mills
Journal:  Drugs       Date:  2005       Impact factor: 9.546

3.  Lavage administration of dilute surfactant in a piglet model of meconium aspiration.

Authors:  Joan Meister; Venkataraman Balaraman; Malia Ramirez; Catherine F T Uyehara; Jeffrey Killeen; Tercia Ku; Donald Person; David Easa
Journal:  Lung       Date:  2004       Impact factor: 2.584

4.  Synthesis and activity of a novel diether phosphonoglycerol in phospholipase-resistant synthetic lipid:peptide lung surfactants().

Authors:  Adrian L Schwan; Suneel P Singh; Jason A Davy; Alan J Waring; Larry M Gordon; Frans J Walther; Zhengdong Wang; Robert H Notter
Journal:  Medchemcomm       Date:  2011-10-19       Impact factor: 3.597

5.  [Not Available].

Authors: 
Journal:  Paediatr Child Health       Date:  2005-02       Impact factor: 2.253

6.  Recommendations for neonatal surfactant therapy.

Authors: 
Journal:  Paediatr Child Health       Date:  2005-02       Impact factor: 2.253

7.  Transfusion-related acute lung injury treated with surfactant in a neonate.

Authors:  T J Wu; R J Teng; K I Tsou Yau
Journal:  Eur J Pediatr       Date:  1996-07       Impact factor: 3.183

8.  New targets for surfactant replacement therapy: experimental and clinical aspects.

Authors:  B Robertson
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  1996-07       Impact factor: 5.747

9.  Nebulisation of surfactants in an animal model of neonatal respiratory distress.

Authors:  T F Fok; M al-Essa; M Dolovich; F Rasid; H Kirpalani
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  1998-01       Impact factor: 5.747

Review 10.  Surfactant replacement therapy.

Authors:  M J Kresch; W H Lin; R S Thrall
Journal:  Thorax       Date:  1996-11       Impact factor: 9.139

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.